Bioresorbable Scaffolds: Clinical Outcomes and Considerations

Davide Capodanno

doi:10.1016/j.iccl.2016.02.005

Bioresorbable Scaffolds: Clinical Outcomes and Considerations

Interv Cardiol Clin. 2016 Jul;5(3):357-363. doi: 10.1016/j.iccl.2016.02.005. Epub 2016 Jun 21.

Author

Davide Capodanno¹

Affiliation

¹ Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, via Citelli 6, Catania 95124, Italy. Electronic address: dcapodanno@gmail.com.

PMID: 28582033
DOI: 10.1016/j.iccl.2016.02.005

Abstract

Bioresorbable scaffolds (BRS) have been engineered to eliminate the theoretic stimulus to late coronary events, a caveat of conventional metallic drug-eluting stents (DESs). Outcome benefits of BRSs over current-generation DESs are expected to accrue after complete bioresorption. Before this timeframe, BRSs need to prove at least similarly safe and effective compared with DESs. Several randomized studies of the Absorb BRS have been made available. Several manufacturers are at the beginning of their line of clinical development of competing BRSs. This article reviews the contemporary clinical outcomes of the Absorb scaffold, and provides an updated state of the art on the other players in the BRS arena.

Keywords: Absorb; BRS; BVS; Biodegradable stents; Bioresorbable scaffolds; Scaffold.

Publication types

Review

MeSH terms

Absorbable Implants*
Coronary Artery Disease / surgery*
Humans
Percutaneous Coronary Intervention / methods*
Prosthesis Design
Tissue Scaffolds*
Treatment Outcome